These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 12224305)

  • 1. [Treatment of patients with Graves' ophthalmopathy by immunosuppressive agent and 99Tc-MDP].
    Pan W; Tan T; Wang Q; Zheng J
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2002 Jun; 19(2):300-1, 323. PubMed ID: 12224305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of technetium-99 methylenediphosphonate on cytokine-induced activation of retro-ocular fibroblasts from patients with Graves' ophthalmopathy.
    Yan SX; Wang Y; Peng GJ; Lu XP; Fu Y
    Nucl Med Commun; 2011 Feb; 32(2):142-6. PubMed ID: 21063232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retrobulbar 99mTc-diethylenetriamine-pentaacetic-acid uptake may predict the effectiveness of immunosuppressive therapy in Graves' ophthalmopathy.
    Ujhelyi B; Erdei A; Galuska L; Varga J; Szabados L; Balazs E; Bodor M; Cseke B; Karanyi Z; Leovey A; Mezosi E; Burman KD; Berta A; Nagy EV
    Thyroid; 2009 Apr; 19(4):375-80. PubMed ID: 19355827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Viral conjunctivitis interfering with the clinical activity score and management of thyroid ophthalmopathy.
    Boboridis KG; Konstas AG; Krassas GE; Georgiadis NS
    Orbit; 2006 Mar; 25(1):27-9. PubMed ID: 16527772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects and safety of 99Tc-MDP in patients with refractory ankylosing spondylitis: a 2-stage (30-week follow-up) clinical trial.
    Xu Y; Zhong Y; Zhao M; Tu L; Fan M; Zhang P; Wei Q; Cao S; Li Q; Liao Z; Lin Z; Pan Y; Jin O; Gu J
    Clin Exp Rheumatol; 2018; 36(3):396-404. PubMed ID: 29148408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel treatment of 99Tc-MDP improves clinical and radiographic results for patients with osteochondral lesions of the talus.
    Liu H; Guo H; Guo S; Wang J; Ye Y; Ma C
    Q J Nucl Med Mol Imaging; 2019 Jun; 63(2):199-206. PubMed ID: 27327630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Practical Guidelines Management of Graves Ophthalmopathy.
    Subekti I; Soewondo P; Soebardi S; Darmowidjojo B; Harbuwono DS; Purnamasari D; Tarigan TJE; Wisnu W; Tahapary DL; Kurniawan F; Sidik M; Nusanti S; Dewiputri S; Suharko H; Suardana GG; Suroyo I; Wulani V; Siswoyo AD; Gondhowiardjo S; Kodrat H
    Acta Med Indones; 2019 Oct; 51(4):364-371. PubMed ID: 32041923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy for Graves' ophthalmopathy.
    Salvi M
    Curr Opin Endocrinol Diabetes Obes; 2014 Oct; 21(5):409-14. PubMed ID: 25105999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy of immunosuppressive treatment of Graves' orbitopathy is not affected by previous anti-thyroid drugs or by radioiodine therapy of Graves' disease.
    Jagiełło-Korzeniowska A; Sokołowski A; Krzentowska-Korek A; Miklaszewska G; Bałdys-Waligórska A
    Endokrynol Pol; 2016; 67(6):554-561. PubMed ID: 28042648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in treatment of active, moderate-to-severe Graves' ophthalmopathy.
    Wiersinga WM
    Lancet Diabetes Endocrinol; 2017 Feb; 5(2):134-142. PubMed ID: 27346786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Latanoprost is effective in reducing high intraocular pressure associated with Graves' ophthalmopathy.
    Gumińska M; Kłysik A; Siejka A; Jurowski P
    Klin Oczna; 2014; 116(2):89-93. PubMed ID: 25345284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Biological treatment options for Graves' ophthalmopathy].
    El Fassi D; Nielsen CH; Hegedüs L
    Ugeskr Laeger; 2008 Jun; 170(24):2128-30. PubMed ID: 18565294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Immunosuppressive therapies in patients with Graves' ophthalmopathy].
    Wang J; Wang YT; Shao JQ; Wang X; Du H
    Zhonghua Nei Ke Za Zhi; 2004 Feb; 43(2):125-7. PubMed ID: 15059413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Comparison of the effectiveness of 131-I and antithyroid drugs in the treatment of Graves' disease in children].
    Chen DY; Chen TH
    Zhonghua Er Ke Za Zhi; 2005 Jul; 43(7):507-9. PubMed ID: 16083551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Corticosteroids for Graves' Ophthalmopathy: Systematic Review and Meta-Analysis.
    Tu X; Dong Y; Zhang H; Su Q
    Biomed Res Int; 2018; 2018():4845894. PubMed ID: 30596092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term remission of steroid-resistant Graves' orbitopathy after administration of anti-thymocyte globulin.
    Świerkot M; Kulawik G; Sarnat-Kucharczyk M; Jagoda K; Mrukwa-Kominek E; Chudek J
    Endokrynol Pol; 2020; 71(2):198-199. PubMed ID: 32096552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent advances in graves ophthalmopathy medical therapy: a comprehensive literature review.
    Li X; Li S; Fan W; Rokohl AC; Ju S; Ju X; Guo Y; Heindl LM
    Int Ophthalmol; 2023 Apr; 43(4):1437-1449. PubMed ID: 36272013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose intravenous glucocorticoid therapy for Graves' ophthalmopathy: where are we now?
    Bahn R
    Thyroid; 2012 Jan; 22(1):1-2. PubMed ID: 22216984
    [No Abstract]   [Full Text] [Related]  

  • 19. [Steroid therapy for Graves' ophthalmopathy].
    Hiromatsu Y
    Nihon Rinsho; 2006 Dec; 64(12):2279-85. PubMed ID: 17154092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effect of 99Tc-MDP on cytokine production by peripheral blood mononuclear cells of patients with rheumatoid arthritis].
    Wu YG; Ma QL; Liu GF
    Hunan Yi Ke Da Xue Xue Bao; 2002 Apr; 27(2):173-5. PubMed ID: 12575354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.